Business
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug development and AI-powered drug discovery to conduct in-depth collaboration in target discovery, drug molecule design and optimization, AI-assisted drug development and clinical translation. The two parties will advance the rollout of demonstrati
About this update from Suzhou Ribo Life Science Co. Ltd. Class H
[{"type":"text","content":"SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug development and AI-powered drug discovery to conduct in-depth collaboration in target discovery, drug molecule design and optimization, AI-assisted drug development and clinical translation. The two parties will advance the rollout of demonstration projects and the translation of research achievements, and accelerate siRNA drug research and development through AI+siRNA joint innovation to address unmet clinical needs.","length":744,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/瑞博生物)","displaySize":"","headline":null,"caption":"(PRNewsfoto/瑞博生物)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":260,"url":"https://media.zenfs.com/en/prnewswire.com/1989684996373cf3185d940c4c298bdf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1K0PFoYr1a7YOEheNJvi2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ1OA--/https://media.zenfs.com/en/prnewswire.com/1989684996373cf3185d940c4c298bdf","width":400,"height":260},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_cPZ30D1wEesLuyP0dDTXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQxNg--/https://media.zenfs.com/en/prnewswire.com/1989684996373cf3185d940c4c298bdf","width":400,"height":260}},"href":"https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Leveraging the RNAi mechanism, siRNA drugs are able to achieve precise silencing of pathogenic genes. With core advantages of extremely broad target spectrum, digital design capability, short development cycles, and high patient compliance due to ultra-long duration, siRNA drugs have spearheaded the "third wave of modern pharmaceuticals". Deep integration with AI technology will further enhance the efficiency and success rate of siRNA drug development, facilitating breakthroughs in "undruggable" targets that remain intractable via conventional approaches, thereby bringing novel therapeutic solutions to patients.","length":639,"tagName":"p"},{"type":"text","content":"Ribo is ...